Respiratory syncytial virus associated hospitalizations in preterm infants of 29 to 32 weeks gestational age using a risk score tool for palivizumab prophylaxis

To evaluate the efficacy of palivizumab in infants of 29 to 32 weeks of gestational age (GA) based on a risk score tool developed for Austria. Retrospective single-center cohort study including all preterm infants of 29 (+0) to 32 (+6) weeks of GA born between 2004 and 2012 at a tertiary care univer...

Descripción completa

Detalles Bibliográficos
Autores principales: Resch, B., Bramreiter, V. S., Kurath-Koller, S., Freidl, T., Urlesberger, B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442239/
https://www.ncbi.nlm.nih.gov/pubmed/28078558
http://dx.doi.org/10.1007/s10096-016-2891-6

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5442239/
https://www.ncbi.nlm.nih.gov/pubmed/28078558
http://dx.doi.org/10.1007/s10096-016-2891-6

Ejemplares similares